Geron Corp

Geron’s telomerase inhibitor strategy fuels investor optimism: despite a negative P/E, its P/B of 3.41 reflects confidence as the company meets Nasdaq’s inducement grant requirements and advances its myeloid‑malignancy pipeline.

Geron’s stock edges up on Dec 24, driven by optimism over its telomerase‑inhibitor pipeline for myeloid cancers.

Geron’s restructuring and IMerge data show telomerase inhibitor imetelstat may turn side‑effect cytopenias into on‑target cancer benefits.

Geron Corp’s telomerase‑inhibitor imetelstat targets myeloid cancers—discover the company’s biotech focus, market performance, and future prospects.

Geron Corporation has announced a series of executive leadership changes aimed at strengthening its commercial focus, including the departure of its current CEO and the appointment of new leaders in key areas such as commercial and scientific strate…